Navigation Links
OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007
Date:10/17/2007

Latest Randomized Clinical Trial Results of First Pro-Healing Stent Also

Featured at Annual Symposium

HONG KONG, Oct. 18 /PRNewswire/ -- OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is the subject of several sessions about innovation in interventional cardiology strategies and device design at this year's Transcatheter Cardiovascular Therapeutics symposium, TCT 2007, which is set for Oct. 20-25 at the Washington Convention Center in Washington, D.C.

The line-up of sessions that feature the first pro-healing stent, which is an alternative to drug-eluting stents, includes:

- Interventional Strategies and Adjunct Pharmacology in ACS and AMI;

Should Specialized DES for AMI be Developed? Early Experience with EPC

Capture Technology; Jan Henk Dambrink, M.D., Ph.D., Department of

Cardiology, ISALA Klinieken, Hospital De Weezenlanden, Zwolle, The

Netherlands; 2:10 p.m. EDT on Oct. 21; Room 151B

- Innovative Devices and Futuristic Concepts: Novel Bare Metal and Drug-

Eluting Stents; The Genous Stent Coating with CD34 Antibodies to

Actively Capture Circulating EPCs: Design Parameters and Effects on

Healing and Thrombogenicity; Michael Kutryk, M.D., clinician scientist

and interventional cardiologist at St. Michael's Hospital, assistant

professor at the University of Toronto; Canada; 3:08 p.m. EDT on Oct.

21; Room 152A

In addition, the latest results from clinical trials of the Genous stent will be discussed by Robbert de Winter, M.D., Ph.D., principal investigator and director of the catheterization laboratory at the Academic Medical Center in Amsterdam. Specifically, de Winter will present:

- Updates from the HEALING studies, AMC "Real World" registry and TRIAS

trial; 4:36 p.m. EDT on Oct. 21; Ballroom C, 3rd floor

- A late-breaking report of six-month clinical outcomes from the TRIAS HR

pilot study: a
'/>"/>

SOURCE OrbusNeich
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
2. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
3. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
4. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
5. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
6. Pharmathenes Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimers Research
7. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimers Research
8. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
10. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... Essential Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by ... , Asia-Pacific , and Rest of ... by MarketsandMarkets, The global market for Eubiotics was valued at ... USD 7.05 Billion by 2020, at a CAGR of 7.4% ...
(Date:8/28/2015)... 2015 The global mHealth ... billion by 2020, growing at a CAGR of 47.6% ... by Grand View Research, Inc. Monitoring services is expected ... 2014 to 2020.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ... rising incidences of chronic diseases such as cancer, heart ...
(Date:8/27/2015)... , Aug. 27, 2015 DURECT Corporation (Nasdaq: ... to present at three upcoming healthcare conferences.  ... CEO, will present at the Rodman & Renshaw Investment ... time. The conference is being held at the St. ... . A live audio webcast of the presentation will ...
Breaking Medicine Technology:Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5DURECT to Participate in Upcoming Healthcare Conferences 2
... symptoms of SLE,disease at 52 Weeks and ... weeks-, ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ ... presentation of Phase 2,trial data demonstrating that ... clinical,measures, was well tolerated and improved quality ...
... June 13, 2007 /PRNewswire/ -- Two studies presented,today ... at peak,plasma levels, nor did it impair middle-of-the-night ... from chronic,insomnia. The results of the studies were ... Professional Sleep Societies,(APSS). , "These data are important ...
Cached Medicine Technology:Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 2Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 3Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 4Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 5
(Date:8/29/2015)... ... August 30, 2015 , ... On September 30, 2015, the Career ... the 10 regionally accredited Maricopa Community Colleges , will be hosting a Job ... pursuing employment information and opportunities. , The Expo has expanded to much more than ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made possible by ... of patients, according to a newly published report. Surviving Mesothelioma has more on ... , The authors of the new paper focus on several types of ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... chronic obstructive pulmonary disease (including emphysema), or asthma, are at higher risk from ... previous heart attack, heart failure or heart-rhythm problems (arrhythmia or irregular heartbeat) are ...
(Date:8/28/2015)... ... 28, 2015 , ... Joining a growing number of hospitals ... management companies to partner with Wound Care Advantage (WCA) to utilize the ... , Transitioning wound care management providers can be a complex undertaking. WCA provides ...
(Date:8/28/2015)... ... August 28, 2015 , ... With the goal of ... for the second year to the Adams County Fairgrounds in Mendon, IL on May ... raise money to support music education in the underfunded school districts of Mendon and ...
Breaking Medicine News(10 mins):Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2
... contain possibly hazardous chemicals called polybrominated diphenyl ethers (PBDEs). ... Standards and Technology and the Environmental Protection Agency of ... yet clear how dangerous these PBDEs are, though some ... structure is strikingly similar to that of PCBs, which ...
... are suffering from mental illness after serving in war-torn ... or longer for treatment// from the National Health Service ... by British Ministry of Defence (MoD) showed 2,123 servicemen ... after returning from Iraq since 2003. More than 320 ...
... has set up a facility in Chennai, the state ... ,Called Poison Control Training and Research Centre, ... It can handle emergency situations like mass poisoning. It ... services and counseling. An intensive care unit, a library, ...
... the hospitals run by NHS trusts, more and more people ... According to the Daily Telegraph, the bed occupancy rates in ... ,Norman Lamb, the health spokesman of the Liberal ... an uphill task to keep patients clean and isolate them. ...
... a tool to help hospitals prepare for disasters ... Electronic Mass Casualty Assessment & Planning Scenarios (EMCAPS) ... as a flu epidemic, bioterrorist attack, flood or ... of victims, wind direction, available medical resources, bacterial ...
... posed by mercury contaminated fish are enormous and especially ... careful about how much// and which fish they eat ... a special issue of the international science journal Ambio. ... Mercury as a Global Pollutant last August in Madison, ...
Cached Medicine News:Health News:Methylmercury in Marine Fish Pose Health Risks to Pregnant Women and Elderly Men 2Health News:Methylmercury in Marine Fish Pose Health Risks to Pregnant Women and Elderly Men 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: